{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:18:31Z","timestamp":1771543111793,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005187","name":"National and Kapodistrian University of Athens","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Urology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ajur.2024.09.007","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T12:53:59Z","timestamp":1734612839000},"page":"357-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of the clinical significance of the expression of immunohistochemical biomarkers Enhancer of zeste homolog 2 and Forkhead box M1 in localized prostate cancer tissue: A Greek retrospective study"],"prefix":"10.1016","volume":"12","author":[{"given":"Sotirios","family":"Koubardas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Goutas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iliana","family":"Mani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Krikou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ourania","family":"Mpatsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harikleia","family":"Gakiopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Alamanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas C.","family":"Lazaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajur.2024.09.007_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajur.2024.09.007_bib2","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.007_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96\u201302\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.09.007_bib4","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2024.09.007_bib5","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ajur.2024.09.007_bib6","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/cncr.24348","article-title":"Predictive models in external beam radiotherapy for clinically localized prostate cancer","volume":"115","author":"Roach","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ajur.2024.09.007_bib7","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2174\/1871520620666200731161810","article-title":"FOXM1-dependent transcriptional regulation of EZH2 induces proliferation and progression in prostate cancer","volume":"21","author":"Tian","year":"2021","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.ajur.2024.09.007_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.ajur.2024.09.007_bib9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.stemcr.2014.12.006","article-title":"EZH2 protects glioma stem cells from radiation-induced cell death in a MELK\/FOXM1-dependent manner","volume":"4","author":"Kim","year":"2015","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.ajur.2024.09.007_bib10","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ajur.2024.09.007_bib11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajur.2024.09.007_bib12","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ajur.2024.09.007_bib13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp 53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ajur.2024.09.007_bib14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrc2223","article-title":"The emerging roles of Forkhead box (Fox) proteins in cancer","volume":"7","author":"Myatt","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajur.2024.09.007_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.03.007","article-title":"FOXM1: a small fox that makes more tracks for cancer progression and metastasis","volume":"92","author":"Khan","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ajur.2024.09.007_bib16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.canlet.2012.09.017","article-title":"Cancer genetics and genomics of human FOX family genes","volume":"328","author":"Katoh","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ajur.2024.09.007_bib17","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1158\/0008-5472.CAN-07-1265","article-title":"Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells","volume":"67","author":"Wang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajur.2024.09.007_bib18","doi-asserted-by":"crossref","first-page":"E3735","DOI":"10.1073\/pnas.1602079113","article-title":"HIFI-\u03b1 activation underlies a functional switch in the paradoxical role of Ezh2\/PRC2 in breast cancer","volume":"113","author":"Mahara","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajur.2024.09.007_bib19","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3390\/biom12111617","article-title":"EZH2 as a prognostic factor and its immune implication with molecular characterization in prostate cancer: an integrated multi-omics in silico analysis","volume":"12","author":"Du","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ajur.2024.09.007_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3760\/cma.j.issn.0366-6999.20122477","article-title":"Role of co-expression of c-Myc, EZH2 and p27 in prognosis of prostate cancer patients after surgery","volume":"126","author":"Li","year":"2013","journal-title":"Chin Med J"},{"key":"10.1016\/j.ajur.2024.09.007_bib21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/pros.20319","article-title":"Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer","volume":"66","author":"Fu","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.ajur.2024.09.007_bib22","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1158\/0008-5472.CAN-11-3546","article-title":"Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer","volume":"72","author":"Ren","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajur.2024.09.007_bib23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/bjc.2014.588","article-title":"Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer\u2014what has gone wrong? A blueprint for the way forward in biomarker studies","volume":"112","author":"Huber","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajur.2024.09.007_bib24","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1097\/00000478-199912000-00004","article-title":"Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression","volume":"23","author":"Brinker","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajur.2024.09.007_bib25","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0046-8177(98)90423-3","article-title":"Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer","volume":"29","author":"Wilcox","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajur.2024.09.007_bib26","first-page":"29","article-title":"Ductal (\u201cendometrioid\u201d) adenocarcinoma of the prostate","volume":"66","author":"Colpaert","year":"1998","journal-title":"Acta Urol Belg"},{"key":"10.1016\/j.ajur.2024.09.007_bib27","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.eururo.2007.12.030","article-title":"Long-term outcome following three-dimensional conformal\/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer","volume":"53","author":"Zelefsky","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.09.007_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000020311","article-title":"Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer","volume":"38","author":"Van Poppel","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.09.007_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf1644","article-title":"The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity","volume":"353","author":"Torres","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ajur.2024.09.007_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature09807","article-title":"Tumour evolution inferred by single-cell sequencing","volume":"472","author":"Navin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ajur.2024.09.007_bib31","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.drudis.2020.11.032","article-title":"Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance","volume":"26","author":"Shih","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ajur.2024.09.007_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ajur.2024.09.007_bib33","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","article-title":"Stem cell fate in cancer growth, progression and therapy resistance","volume":"18","author":"Lytle","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajur.2024.09.007_bib34","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/cas.14722","article-title":"Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients","volume":"112","author":"Shiota","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajur.2024.09.007_bib35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2478\/raon-2021-0017","article-title":"Prognostic factors in postoperative radiotherapy for prostate cancer\u2014tertiary center experience","volume":"55","author":"Miszczyk","year":"2021","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.ajur.2024.09.007_bib36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.semradonc.2013.01.002","article-title":"Prognostic factors for newly diagnosed prostate cancer and their role in treatment selection","volume":"23","author":"Crook","year":"2013","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ajur.2024.09.007_bib37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5301\/uro.5000166","article-title":"Clinical, pathological and molecular prognostic factors in prostate cancer decision-making process","volume":"83","author":"Pugliese","year":"2016","journal-title":"Urologia"},{"key":"10.1016\/j.ajur.2024.09.007_bib38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.7150\/jca.28099","article-title":"High FOXM1 expression is a prognostic marker for poor clinical outcomes in prostate cancer","volume":"10","author":"Kim","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.ajur.2024.09.007_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11010-020-03739-1","article-title":"Baicalin suppresses the cell cycle progression and proliferation of prostate cancer cells through the CDK6\/FOXM1 axis","volume":"469","author":"Yu","year":"2020","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.ajur.2024.09.007_bib40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1541-7786.MCR-16-0262","article-title":"Metabolic profiling in formalin-fixed and paraffin-embedded prostate cancer tissues","volume":"15","author":"Cacciatore","year":"2017","journal-title":"Mol Cancer Res"}],"container-title":["Asian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221438822400136X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221438822400136X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:07:01Z","timestamp":1757776021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221438822400136X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S221438822400136X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajur.2024.09.007","relation":{},"ISSN":["2214-3882"],"issn-type":[{"value":"2214-3882","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of the clinical significance of the expression of immunohistochemical biomarkers Enhancer of zeste homolog 2 and Forkhead box M1 in localized prostate cancer tissue: A Greek retrospective study","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajur.2024.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editorial Office of Asian Journal of Urology. Publishing services by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}